Neuronetics Expands NeuroStar® Advanced Therapy’s Proprietary TrakStar® Platform
23 févr. 2023 08h56 HE
|
Neuronetics
MALVERN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call
22 févr. 2023 16h35 HE
|
Neuronetics
MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Sponsors the 5th International Brain Stimulation Conference
21 févr. 2023 08h53 HE
|
Neuronetics
MALVERN, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer
16 févr. 2023 16h12 HE
|
Neuronetics
MALVERN, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Updated Medicare Policy Expanding Access to NeuroStar TMS Therapy through Nurse Practitioners
10 févr. 2023 16h15 HE
|
Neuronetics
MALVERN, Pa., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics and Greenbrook TMS Announce Six Year Exclusive Partnership
19 janv. 2023 08h30 HE
|
Neuronetics
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 janv. 2023 16h29 HE
|
Neuronetics
MALVERN, Pa., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
17 janv. 2023 08h32 HE
|
Neuronetics
MALVERN, Pa., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Settles Litigation Against BrainsWay
10 janv. 2023 08h00 HE
|
Neuronetics
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
09 janv. 2023 08h30 HE
|
Neuronetics
MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...